Parelsnoer institute biobank hereditary colorectal cancer: A joint infrastructure for patient data and biomaterial on hereditary colorectal cancer in the Netherlands

Each year approximately 15,000 patients are diagnosed with colorectal cancer (CRC) in the Netherlands, of whom 5-10% are associated with a hereditary syndrome. To enable future research into hereditary CRC, we established a collaborative biobank for hereditary CRC in all eight University Medical Centers (UMCs) in the Netherlands in 2009. This Biobank Hereditary CRC is part of the Parelsnoer Institute (PSI), which is funded by the Dutch Federation of UMCs and the Dutch Government. Besides the multicenter collaboration, the multidisciplinary nature of this biobank - involving Gastroenterology, Genetics and Surgery - is essential for its functionality and value.Patients at increased risk of hereditary CRC and/or Polyposis, or with a proven germline mutation causing CRC and/or Polyposis are included. Both clinical data (demographic data, details on medical and family history, information on surveillance, endoscopy and surgery, results of microsatellite instability and molecular genetic tests) and biomaterial (DNA, plasma, serum and tissue) are collected in a standardized manner

Antimicrobial and antiviral effect of High-Temperature Short-Time (HTST) pasteurization applied to human milk

In the United States, concerns over the transmission of infectious diseases have led to donor human milk generally being subjected to pasteurization prior to distribution and use. The standard method used by North American milk banks is Holder pasteurization (63 degrees C for 30 minutes). The authors undertook an experiment to validate the effects of a high-temperature short-time (HTST) pasteurization process (72 degrees C for 16 seconds) on the bioburden of human milk. It was concluded that HTST is effective in the elimination of bacteria as well as of certain important pathogenic viruse

Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates

BACKGROUND: Pathogen contamination, causing transfusion-transmitted diseases, is an ongoing concern in transfusion of cellular blood products. In this explorative study, the pathogen-inactivating capacity of UVC irradiation in platelet (PLT) concentrates was investigated. The dose dependencies of inactivation of several viruses and bacteria were compared with the effect on PLT quality. STUDY DESIGN AND METHODS: The potential of UVC irradiation was studied with a range of lipid-enveloped (LE) and non-lipid-enveloped viruses (NLE) and bacteria. LE viruses were bovine viral diarrhea virus (BVDV), human immunodeficiency virus (HIV), pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), and vesicular stomatitis virus (VSV). NLE viruses were canine parvovirus (CPV) and simian virus 40 (SV40). Bacteria were Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, and Bacillus cereus. After spiking and irradiation, samples were tested for residual infectivity and reduction factors (RFs) were calculated. Furthermore, the effect of UVC irradiation on PLT quality was determined by measuring in vitro quality variables. RESULTS: A UVC dose of 500 J per m(2) resulted in acceptable PLT quality (as measured by pH, lactate production, CD62P expression, and exposure of phosphatidylserine) and high RFs (>4 log) for CPV, TGEV, VSV, S. epidermidis, S. aureus, and E. coli. Intermediate RFs (approx. 3 log) were observed for BVDV, PRV, and B. cereus. Low RFs (approx. 1 log) were found for HIV and SV40. No differences in virus reduction were observed between cell-free and cell-associated virus. CONCLUSION: UVC irradiation is a promising pathogen-reducing technique in PLT concentrates, inactivating bacteria, and a broad range of viruses (with the exception of HIV) under conditions that have limited effects on PLT quality. Further optimization of the UVC procedure, however, is necessary to deal with blood-borne viruses like HI

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru

Parel Infammatory Bowel Disease (IBD)

Objective is to better understand the causes of this group of conditions and the effectiveness of medicines and treatment for 60,000 patients with a chronic inflammation of the digestive tract. 4317 donors, male and female. Between 17 and 90 years of age. Biological samples: DNA, tissue (paraffin preserved and/or cryo preserved) faeces, Seru